Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Directors' Disclosure

29 Nov 2013 07:00

RNS Number : 2260U
Iofina PLC
29 November 2013
 



29 November 2013

 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Directors' Disclosure

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, announces a change in the beneficial ownership in the share capital of the Company for George Lantz, Chief Executive Officer, and Jeff Ploen, Non-Executive Deputy Chairman.

 

J. Paul Consulting, Inc. (a company in which Jeff Ploen has the sole beneficial interest) has granted to Mr Lantz 125,000 options over such number of ordinary shares in the capital of the Company held by J. Paul Consulting, Inc. with an exercise price per share of £1.51, being the closing share price on the day Mr Lantz joined the Company, with 33.3% of such options vested at grant date, and 33.3% to vest at each of 19 September 2014 at 19 September 2015.

 

Lance Baller, the former Chief Executive Officer of IOF, has granted to Mr Lantz 125,000 options over such number of ordinary shares in the capital of the Company held by Mr Baller with an exercise price per share of £1.51, being the closing share price on the day Mr Lantz joined the Company, with 33.3% of such options vested at grant date, and 33.3% to vest at each of 19 September 2014 at 19 September 2015.

 

Following the grant of options the revised holdings of Mr Lantz and Mr Ploen are set out below:

 

Director

Number of Shares

% of issued share capital

Total Number of Shares Under Option

Exercise Price

George Lantz

26,433

0.02

500,000

151p

Jeff Ploen

9,400,000*

7.39

Nil

* Includes 1,200,000 Shares held by J Paul Consulting, Inc.

 

Each of J Paul Consulting, Inc. and Lance Baller is prohibited from selling the aforementioned number of shares as are required to satisfy their undertaking to Mr Lantz. The Company is not a party to the arrangements agreed between Mr Ploen, Mr Baller and Mr Lantz respectively, both of which are private transactions agreed between them.

 

 

For further information, please contact:

 

Gary Gatchell, Finance DirectorTel: +44 (0) 20 3006 3135Simon Holden, Company SecretaryTel: +44 (0) 7800 500 097

Iofina plcwww.iofina.com 

 

Ben Colegrave/Chris Sim/James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto/Anna Legge

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUWSNROUAAUAA
Date   Source Headline
5th Jun 20267:00 amRNSAgreement Signed for Additional Brine Water Supply
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.